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The ever increasing social cost that society pays for illness and disease are currently steadily increasing in many
countries in the world today. These changes in society becomes a major financial burden that activates politicians
and health care organizations in order to find new solutions. Biobanks are becoming the new powerful modality
within the field of modern Life Science, that is expected to be important in the proactive awareness of patient
health status. Biobanks are also expected to promote the developments of targeted treatments with personalized
indicator assays, for effective use of Personalized Medicine treatments in the near future.
The reason for these effects of growing health care costs
we are experiencing springs from several changes and
developments, such as increased patient demands, patient
awareness of quality of life, and an increasing global
population. Last but not least, the increasing number of
elderly people, and the health care implications for future
technology developments, are challenges that we need to
address in order to be able to be pro-active and build a
future plan that meets the resources that will become evi-
dent with time. These future developments were recently
highlighted in a"White Paper” by representatives from
Pharma industry, academic research institutes, compa-
nies that are technology platform providers and medical
health institutions in Japan, a country with an expected
elderly population of 40% in 2050, [1].
We have reached a point where the bioinformatic
developments have given us the basis for taking on the
sequencing of the “Human Proteome”,t h a ti sc o d e db y
the genome, ever since the last decade when the Human
Genome Project was announced by Bill Clinton and
Tony Blair, as a scientific milestone. The gene centric
Human Proteome Project (HPP) approach was recently
initiated by HUPO, at the 9th World Congress in Sydney,
2010, where research teams established chromosome
consortia. The start of this HPP chromosome initiative
will need major effort and builds within the UniProt
database, as well as establishment of novel informatic
tools that can aid in delivering on the sequence content
of the Human Proteome. Given this upcoming scientific
milestone challenge ahead of us, the logical question at
hand is: What is the best way forward in getting clinical
and disease understanding with the gene coded protein
sequences at hand?
One important opportunity could be the current activ-
ities on building Biobank archives. Currently, there are
major interests and dedicated projects with substantial
resources to build biobanking facilities around the world.
Biobanks hold archives of population, and disease-based
patient samples that offer a highly valuable sample collec-
tion that could form the future knowledge base to the
scientific community. Clinical registers that describe the
sample history and the diagnosis are of high value, that
strive to correlate biological changes in disease to
changes on a molecular level.
Clearly there are the expectations from politicians and
health care leadership, that by building large collections
of highly standardized and well characterized patient
samples, there will be a future scientific solution to many
of the challenges we have by treating patients today. In
order to be able to build these Biobanks with high quality
standards, as well as the procedures whereby access to
these treasures needs to include the protection of patient
integrity. Clearly, ethical standards and data management
procedures are central when embarking into this new
scale of sample and data processing endeavor.
No doubt there are major Biobank stakeholders in this
new field, where major investments are currently being
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Biomarker deliverables, such as preventive and drug-
targeted biomarkers, as well as new imaging diagnostic
technologies. These new conceptual developments are
especially urgent due to a high unmet need within dis-
eases such as cancers, obesity, diabetes, cardiovascular
diseases, and neurodegenerative diseases. Introducing
the Biobank concept as a new powerful modality within
the field of modern Life Science, is expected to be
important in pro-active awareness of patient health sta-
tus. The pro-active concept should be seen as the future
for many countries, instead of the act-on-demand proce-
dure, where the awareness of treatment occurs when the
patient already has serious disease advancement. Most
countries act on patient disease onset where the costs
and prevention of disease are found to be less optimal,
than in countries where pro-active health-status check
up is the standard procedure. Biobanks are also
expected to promote the developments of targeted treat-
ments with personalized indicator assays, for effective
use of Personalized Medicine treatments in the near
future[2].
Large biobank facilities equipped with robotics and
automated sample processing will also become a large
asset to drug companies. As the pharmaceutical industry
has passed the period of poor candidate drug genera-
tion, the filled up pipelines of drug compounds can now
readily be processed through a validation process utiliz-
ing selected and dedicated clinical material from Bio-
Sample repositories around the world. In addition, each
biofluid and/or tissue sample will most probably have
associated clinical data, from where the patient cohorts
can be composed. It is also envisioned that the Biobank-
ing initiatives will generate a whole new dimension of
data sets from expression studies. This new data will be
a valuable delivery, and payback for accessing the treas-
ures within Biobanks. It is with great interest that we
will follow the maturation of the mechanistic disease
pathophysiology, where the HUPO Chromosome Con-
sortia in collaborative efforts with the Proteomics
society will build the future basis of the human pro-
teome. All of the delivered outcomes will be publicly
available in UniProt [3].
Another objective that needs to be met, will be the
protein data integration, with functional networks that
will provide us with a comprehensive data-set, to be
used as a public resource. How big role the Biobanks
will play in all of these scientific milestone develop-
ments, and whether this will become the Holy Grail,
and whether the benefit by preventive and participatory
medicine for patients combined with stratified diagnos-
tics developments - that still remains to be proven by all
of us in the scientific, and industrial community.
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